신약 기술 반환된 CG인바이츠, 근거있는 자신감

CG Invitro transforms the CG-806 drug development setback into a strategic pivot toward digital healthcare, leveraging government K-Digital Health initiatives and a 40-company alliance around its InvitesLoop genomics-based AI platform. This shift reflects the industry's growing recognition that AI-driven disease prediction and data analytics represent a more scalable path than traditional drug development. The company's ability to turn regulatory failure into ecosystem leadership positions it to capture emerging value in Korea's healthcare innovation landscape.